Study Summary
This trial is testing two different ways to close surgical ports. One is 2-Octylcyanoacrylate and the other is n-butyl-2-cyanoacrylate.
- Contact Dermatitis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: 6 weeks
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Swiftset
1 of 2
Dermabond
1 of 2
Active Control
186 Total Participants · 2 Treatment Groups
Primary Treatment: Swiftset · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does Swiftset meet the criteria for safety and efficacy set by the FDA?
"There is some evidence from earlier phases that Swiftset is effective, as well as data from multiple rounds of testing that support its safety--our team rates it a 3." - Anonymous Online Contributor
Are we still able to enroll new participants for this clinical study?
"This medical trial is currently looking for patients to enroll. According to the information on clinicaltrials.gov, the trial was originally posted on June 29th, 2022 and was last updated on August 11th, 2022." - Anonymous Online Contributor